• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms.

作者信息

Hanley Colleen M, Robinson Victoria M, Kowey Peter R

机构信息

From the Cardiology Division (C.M.H., P.R.K.) and Lankenau Institute for Medical Research (V.M.R., P.R.K.), Lankenau Medical Center, Wynnewood, PA.

出版信息

Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e002479. doi: 10.1161/CIRCEP.115.002479.

DOI:10.1161/CIRCEP.115.002479
PMID:26936819
Abstract
摘要

相似文献

1
Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms.心房颤动抗心律失常药物的研发现状：新药与新分子机制
Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e002479. doi: 10.1161/CIRCEP.115.002479.
2
Innovative Therapeutics for Atrial Fibrillation: Imminent Breakthroughs or Much Ado About Nothing?心房颤动的创新疗法：即将取得突破还是小题大做？
J Cardiovasc Pharmacol. 2015 Nov;66(5):409-11. doi: 10.1097/FJC.0000000000000319.
3
Novel K+ Channel Targets in Atrial Fibrillation Drug Development--Where Are We?心房颤动药物研发中的新型钾离子通道靶点——我们进展如何？
J Cardiovasc Pharmacol. 2015 Nov;66(5):412-31. doi: 10.1097/FJC.0000000000000277.
4
The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.钠通道阻滞剂作为一种心房颤动抑制策略的过去、现在及潜在的未来。
J Cardiovasc Pharmacol. 2015 Nov;66(5):432-40. doi: 10.1097/FJC.0000000000000271.
5
Medical management of atrial fibrillation: future directions.心房颤动的医学管理：未来方向
Heart Rhythm. 2007 Mar;4(3 Suppl):S91-4. doi: 10.1016/j.hrthm.2006.12.022. Epub 2006 Dec 15.
6
[New class III antiarrhythmic drugs for treatment of atrial fibrillation].用于治疗心房颤动的新型III类抗心律失常药物
Kardiologiia. 2012;52(11):56-65.
7
Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.维纳卡兰转复心房颤动的药理学：支持 ESC 指南的证据。
Europace. 2014 Feb;16(2):162-73. doi: 10.1093/europace/eut274. Epub 2013 Oct 9.
8
Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy.钙激活钾通道在心房颤动病理生理学及治疗中的作用
J Cardiovasc Pharmacol. 2015 Nov;66(5):441-8. doi: 10.1097/FJC.0000000000000249.
9
Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.用于心房颤动急性转复的新型药物：聚焦于维纳卡兰
Recent Pat Cardiovasc Drug Discov. 2011 Jan;6(1):1-8. doi: 10.2174/157489011794578428.
10
[Atrial fibrillation: where is the border between pure antiarrhythmic and non-antiarrhythmic medicines?].[心房颤动：纯抗心律失常药物与非抗心律失常药物的界限在哪里？]
Kardiologiia. 2012;52(2):85-90.

引用本文的文献

1
Biomimetic Approaches in the Development of Optimised 3D Culture Environments for Drug Discovery in Cardiac Disease.用于心脏病药物研发的优化3D培养环境开发中的仿生方法
Biomimetics (Basel). 2025 Mar 26;10(4):204. doi: 10.3390/biomimetics10040204.
2
Advances in basic and translational research in atrial fibrillation.心房颤动的基础和转化研究进展。
Philos Trans R Soc Lond B Biol Sci. 2023 Jun 19;378(1879):20220174. doi: 10.1098/rstb.2022.0174. Epub 2023 May 1.
3
Meta‑analysis of the efficacy and safety of nifekalant in the conversion of atrial fibrillation.
尼非卡兰转复心房颤动疗效与安全性的Meta分析
Exp Ther Med. 2022 Dec 7;25(1):56. doi: 10.3892/etm.2022.11755. eCollection 2023 Jan.
4
Human Atrial Cardiac Microtissues for Chamber-Specific Arrhythmic Risk Assessment.用于特定腔室心律失常风险评估的人心脏心房微组织
Cell Mol Bioeng. 2021 Sep 29;14(5):441-457. doi: 10.1007/s12195-021-00703-x. eCollection 2021 Oct.
5
Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation.心房颤动的口服抗凝和抗心律失常药物治疗
J Innov Card Rhythm Manag. 2018 Dec 15;9(12):3446-3452. doi: 10.19102/icrm.2018.091201. eCollection 2018 Dec.
6
Facilitated electrical cardioversion: does the selection of the antiarrhythmic drug matter?药物辅助电复律：抗心律失常药物的选择重要吗？
Int J Cardiol Heart Vasc. 2019 Sep 1;24:100416. doi: 10.1016/j.ijcha.2019.100416. eCollection 2019 Sep.
7
Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging.用于心房颤动的抗心律失常药物：即将出现新的进展。
Int J Cardiol Heart Vasc. 2018 Sep 13;21:11-15. doi: 10.1016/j.ijcha.2018.08.005. eCollection 2018 Dec.
8
Increased thin filament activation enhances alternans in human chronic atrial fibrillation.增加细肌丝激活可增强人心房颤动慢性期的折返。
Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1453-H1462. doi: 10.1152/ajpheart.00658.2017. Epub 2018 Aug 24.
9
Mechanisms and Drug Development in Atrial Fibrillation.心房颤动的机制与药物开发。
Pharmacol Rev. 2018 Jul;70(3):505-525. doi: 10.1124/pr.117.014183.
10
Synaptic Plasticity in Cardiac Innervation and Its Potential Role in Atrial Fibrillation.心脏神经支配中的突触可塑性及其在心房颤动中的潜在作用。
Front Physiol. 2018 Mar 20;9:240. doi: 10.3389/fphys.2018.00240. eCollection 2018.